tbuckley/cabot-search huggingface dataset:
A Telemedicine Approach For Assessment, Empowerment And Triage For COVID-19 Patients with Comorbidities
Authors: Bijay Patni
Journal: Metabolism (2021)

Background: Obesity is associated with the development of Insulin resistance (IR) and the metabolic syndrome (MS).However, it is still unknown whether the stage of life that obesity has developed offers a risk regardless of the individual's adiposity level in adulthood.Objective: To evaluate the association between MS, obesity onset and the TG / HDL-c ratio in women with severe obesity and to establish cutoff points for the TG/HDL-c ratio considering the obesity onset.Methods: Forty-seven women with severe obesity who will undergo bariatric surgery were evaluated.Anthropometric and metabolic parameters were measured and the HOMA-IR and the TG / HDL-c ratio were calculated.The volunteers were grouped according obesity onset.The Receiver Operating Characteristic (ROC) was explored and built to define cutoff points for TG/HDL-C fractions as predictors of MS.Results: The prevalence of women with MS was 76,59%.Most of the sample (63.8%) reported having started obesity in adulthood.Women who developed obesity during infancy/ adolescence had higher weight (p=0.008),body mass index (p=0.031),and hip circumference (p=0.036)compared to those who developed in adulthood; however, no association was found between obesity onset with SM.The TG/HDL-C cutoff points established for those who developed early and late obesity were 2.30 and 2.19, respectively.Conclusion: The life phase of obesity development was not related with MS, however, women with a diagnosis of early obesity had higher anthropometric markers of adiposity.The TG/HDL-c ratio might be useful as a predictor of MS according to the early or late development of obesity.
Abstract 12188: Home Blood Pressure Variability is an Independent Cardiovascular Risk in High-Risk Hypertensives With Advanced Arterial Stiffness: The J-HOP Study
Authors: Kazuomi Kario, Satoshi Hoshide, Hiroshi Kanegae
Journal: Circulation (2018)

Background: Home blood pressure (HBP) variability (HBPV) is reported to be a cardiovascular disease (CVD) risk independently of office and the average of HBPs. Whether the impact of HBPV on CVD is ...
AMIにおけるHANPとニコランジルの併用療法は心筋回復,心機能改善,左室リモデリング抑制に有用か?
Authors: Toyama Takuji, Seki Hidenori, Tomono Junichi, Yano Hideki, Tsuru Toshie, Kan Hakuken, Yanagisawa Saburo, Yamashita Eiji, Tsurugaya Hideki, Adachi Hitoshi, Hoshizaki Hiroshi, Ooshima Shigeru, Taniguchi Koichi
Journal: Circulation (2008)
Asymptomatic SARS-CoV-2 Infections Among Persons Entering China From April 16 to October 12, 2020
Authors: Ruiqi Ren, Yanping Zhang, Qun Li, Jennifer M. McGoogan, Zijian Feng, George F. Gao, Zunyou Wu
Journal: JAMA (2021)

This population epidemiology study characterizes trends in the prevalence of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among international entrants testing positive for SARS-CoV-2 at Chinese border checkpoints between mid-April and mid-October 2020.
Inhibition of the Integrin αVβ3 Improves the Immune and Anti-Lymphoma Effects of Bexarotene in Cutaneous T-Cell Lymphoma (CTCL)
Authors: Maria Florencia Cayrol, Maria Mercedes Debernardi, Maria Victoria Revuelta, Alejandra Paulazo, Maria Nieves Calvo Vidal, Jude M Phillip, Helena Sterle, Maria Celeste Diaz Flaque, Graciela Cremaschi, Leandro Cerchietti
Journal: Blood (2017)
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Authors: S. Popat, A. Curioni-Fontecedro, V. Polydoropoulou, R. Shah, M. O’Brien, A. Pope, P. Fisher, J. Spicer, A. Roy, D. Gilligan, O. Gautschi, E. Nadal, W.-D. Janthur, R. López Castro, R. García Campelo, H. Roschitzki-Voser, B. Ruepp, S. Rusakiewicz, S. Peters, R.A. Stahel
Journal: Annals of Oncology (2019)
Childhood vaccination and allergy: A systematic review and meta‐analysis
Authors: Samidi Navaratna, Marie J. Estcourt, John Burgess, Nilakshi Waidyatillake, Elizabeth Enoh, Adrian J. Lowe, Rachel Peters, Jennifer Koplin, Shyamali C. Dhamage, Caroline J. Lodge
Journal: Allergy (2021)

As the rise in prevalence of allergic diseases worldwide corresponds in time with increasing infant vaccination, it has been hypothesized that childhood vaccination may increase the risk of allergic disease. We aimed to synthesize the literature on the association between childhood vaccination and allergy.We searched the electronic databases PubMed and EMBASE (January 1946-January 2018) using vaccination and allergy terms.Two authors selected papers according to the inclusion criteria. Pooled effects across studies were estimated using random-effects meta-analysis. Due to inadequate number of homogeneous publications on newer and underused vaccines, meta-analysis was limited to allergic outcomes following administration of (Bacillus Calmette-Guérin) BCG, measles or pertussis vaccination. The review was prospectively registered in the PROSPERO systematic review registry (NO: CRD42017071009).A total of 35 publications based on cohort studies and 7 publications based on randomized controlled trials (RCTs) met the inclusion criteria. RCTs: From 2 studies, early vaccination with BCG vaccine was associated with a reduced risk of eczema (RR = 0.83; 95% CI = 0.73-0.93; I2 = 0%) but not food allergy or asthma. No association was found between pertussis vaccine and any allergic outcome based on a single RCT.Childhood measles vaccination was associated with a reduced risk of eczema (RR = 0.65; 95% CI = 0.47-0.90, I2 = 0.0%), asthma (RR = 0.78; 95% CI = 0.62-0.98, I2 = 93.9%) and, with a similar, statistically non-significant reduction in sensitization (RR = 0.78; 95% CI = 0.61-1.01, I2 = 19.4%).We found no evidence that childhood vaccination with commonly administered vaccines was associated with increased risk of later allergic disease. Our results from pooled analysis of both RCTs and cohort studies suggest that vaccination with BCG and measles vaccines were associated with a reduced risk of eczema.
Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates
Authors: Gaïa Zirka, Philippe Robert, Julia Tilburg, Victoria Tishkova, Chrissta X. Maracle, Paulette Legendre, Bart J. M. van Vlijmen, Marie-Christine Alessi, Peter J. Lenting, Pierre-Emmanuel Morange, Grace M. Thomas
Journal: Blood (2021)
Gestational Diabetes History and Glucose Tolerance After Pregnancy Associated With Coronary Artery Calcium in Women During Midlife
Authors: Erica P. Gunderson, Baiyang Sun, Janet M. Catov, Mercedes Carnethon, Cora E. Lewis, Norrina B. Allen, Stephen Sidney, Melissa Wellons, Jamal S. Rana, Lifang Hou, John Jeffrey Carr
Journal: Circulation (2021)

Gestational diabetes (GD) leads to earlier onset and heightened risk of type 2 diabetes, a strong risk factor for cardiovascular disease (CVD). However, it is unclear whether attaining normoglycemia can ameliorate the excess CVD risk associated with GD history. This study sought to evaluate GD history and glucose tolerance after pregnancy associated with coronary artery calcification (CAC) in women, a manifestation of atherosclerotic CVD and a predictor of CVD clinical events.
Denture as an unexpected cause of obstructive jaundice
Authors: Alessandro Pezzoli, Viviana Cifalà, Elena Pizzo, Riccardo Solimando, Loredana Simone, Rosario Arena, Alberto Merighi
Journal: Endoscopy (2021)

A 78-year-old woman who presented with jaundice and fever was referred from another hospital to our endoscopy unit. Her laboratory tests revealed a total bilirubin concentration of 11.7 µmol/L. Computed tomography (CT) scans revealed dilatation of the main biliary duct and the presence of a foreign body in the peripapillary area ([Fig. 1]). The appearance of the foreign body was suggestive of a denture, and the patient reported having involuntary ingested, 3 days previously, a denture that had been implanted many years ago. We performed an endoscopic retrograde cholangiopancreatography (ERCP), which revealed a protruding papilla with the appearance of an impacted stone. We started to perform a sphincterotomy using a precut needle-knife and completed it with a standard sphincterotome. After this, the denture was immediately expelled and allowed to pass into the duodenum ([Video 1]). In the following days, the patient’s total bilirubin level decreased and she was discharged home.
Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation
Authors: Edgar Delgado-Eckert, Anna James, Delphine Meier-Girard, Maciej Kupczyk, Lars I. Andersson, Apostolos Bossios, Maria Mikus, Junya Ono, Kenji Izuhara, Roelinde Middelveld, Barbro Dahlén, Mina Gaga, Nikos M. Siafakas, Alberto Papi, Bianca Beghe, Guy Joos, Klaus F. Rabe, Peter J. Sterk, Elisabeth H. Bel, Sebastian L. Johnston, Pascal Chanez, Mark Gjomarkaj, Peter H. Howarth, Ewa Niżankowska-Mogilnicka, Sven-Erik Dahlén, Urs Frey
Journal: Journal of Allergy and Clinical Immunology (2021)
Nausea and the Brain: The Chemoreceptor Trigger Zone Enters the Molecular Age
Authors: Wenfei Han, Ivan E. de Araujo
Journal: Neuron (2021)

Area postrema in brainstem has long been known to trigger emesis by detecting blood-borne toxins and pathogens. In this issue, Zhang and colleagues provide a single-cell molecular atlas of this region, opening new possibilities for harnessing its neurons in vivo.
Abstract 21199: Left Ventricular Systolic Dyssynchrony; Prevalence and Determinants in a Population-Based Cohort
Authors: Ben Jacobson, Kate Abhayaratna, Christine Brown, Walter P Abhayaratna
Journal: Circulation (2010)

Background:  Left ventricular (LV) systolic dyssynchrony, quantified by the standard deviation of time-to-peak systolic myocardial velocity (Ts-SD), has been shown to be prevalent in various clinical and subclinical cardiac diseases. An evaluation of the determinants of LV dyssynchrony in unselected populations is likely to facilitate a better understanding of the pathophysiology and natural history of LV dysfunction.   Aim:  To assess the prevalence and clinical/echocardiographic determinants of LV systolic dyssynchrony in a population-based sample of older adults.   Methods:  Cardiac structure and function was assessed by echocardiography in the first 451 participants of a prospective population-based cohort study (mean age 75.3±5.9yrs, 49% men). LV systolic synchrony was quantitated as Ts-SD, and measured as the time from QRS-onset to peak systolic velocity at 6 basal segments in the apical views.   Results:  Of the 451 subjects (mean Ts-SD: 46±26ms), 311 (69%) had LV systolic dyssynchrony, previously defined as Ts-SD>30ms. Ts-SD was higher in women (50±24ms vs. 41±26ms; p=0.0003). Clinical correlates of Ts-SD included a history of systemic hypertension; systolic blood pressure and pulse pressure; increased heart rate; and body mass index (Table). Ts-SD increased with LV total systolic period, LV end-diastolic size; LV mass index; and LV filling pressure as assessed by E/e9. In multivariable analysis, independent predictors of Ts-SD included sex, heart rate, pulse pressure, and LV filling pressure (all p   Conclusions:  In an unselected population of older adults, LV systolic dyssynchrony, as assessed by Ts-SD, is highly prevalent and is determined by factors related to LV afterload, total systolic time, and intrinsic properties of LV structure and diastolic function.
Critical evaluation of the methodology used by Wilson-Davies et al., (2020) entitled “Concerning the Optigene Direct LAMP assay, and it`s use in at-risk groups and hospital staff”
Authors: Dr Veronica Fowler, Dr Angela Douglas, Professor Keith Godfrey, Professor Anthony Williams, Professor Andrew Beggs, Stephen Kidd, Dr Nick Cortes, Professor Mark Wilcox, Dr Kerrie Davies, Melanie Smith, Professor Dame Sue Hill
Journal: Journal of Infection (2021)
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
Authors: Manish A. Shah, Gyorgy Bodoky, Alexander Starodub, David Cunningham, Desmond Yip, Zev A. Wainberg, Johanna Bendell, Dung Thai, Joyce He, Pankaj Bhargava, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2021)

Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.This phase III, randomized, double-blinded, placebo (PBO)-controlled multicenter study investigated the efficacy and safety of mFOLFOX6 with and without ADX in patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma. Random assignment was 1:1 to mFOLFOX6 + ADX or mFOLFOX6 + PBO. ADX/PBO 800 mg was infused on days 1 and 15 of each 28-day cycle. Protocol therapy was given until disease progression or intolerance. The primary end point was overall survival (OS), and secondary end points were progression-free survival (PFS), objective response rate (RECIST 1.1), and safety.Between September 2015 and May 2017, 432 patients were randomly assigned, 218 to ADX and 214 to PBO. The median OS was 12.5 versus 11.8 months in the ADX and PBO groups, respectively. The median PFS was 7.5 versus 7.1 months in the ADX and PBO groups, respectively. The objective response rate was 51% in the ADX group and 41% in the PBO group. Among the subgroup analyses, patients of age ≥ 65 years had an improved OS and PFS with ADX versus PBO; the P values and CIs were not adjusted for multiplicity. There were no meaningful differences in the safety profile of the ADX versus PBO groups.The addition of ADX to mFOLFOX6 did not improve OS in unselected patients with untreated human epidermal growth factor receptor 2-negative gastric or GEJ adenocarcinoma.
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial
Authors: Julie Dubourg, Pascale Fouqueray, Carole Thang, Jean-Marie Grouin, Kohjiro Ueki
Journal: Diabetes Care (2021)

OBJECTIVE The aim of this study was to investigate the efficacy and safety of imeglimin, the first in a new class of oral antidiabetic agent, in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This was a double-blind, randomized, parallel-group, placebo-controlled phase 3 trial in 30 sites in Japan. Eligible participants were individuals aged ≥20 years with type 2 diabetes treated with diet and exercise, stable for ≥12 weeks prior to screening, and whose HbA1c was 7.0–10.0% (53–86 mmol/mol). Patients were randomly assigned (1:1) to either oral imeglimin (1,000 mg twice daily) or matched placebo for 24 weeks. Investigators, participants, and the sponsor of the study remained blinded throughout the trial. The primary end point was the change in mean HbA1c from baseline to week 24, and the key secondary end point was the percentage of responders (according to two definitions) at week 24. RESULTS Between 26 December 2017 and 1 February 2019, 106 and 107 patients were randomly assigned to treatment with imeglimin and placebo, respectively. Compared with placebo, the adjusted mean difference in change from baseline HbA1c at week 24 was −0.87% (95% CI −1.04 to −0.69 [−9.5 mmol/mol; 95% CI −11.4 to −7.5]; P &amp;lt; 0.0001). Forty-seven (44.3%) patients reported ≥1 adverse event in the imeglimin group versus 48 adverse events (44.9%) in the placebo group. CONCLUSIONS Imeglimin significantly improved HbA1c in Japanese patients with type 2 diabetes compared with placebo and had a similar safety profile to placebo. Imeglimin represents a potential new treatment option for this population.
THU0141 A META-ANALYSIS FOR THE PREVALENCE AND RISK FACTORS OF SARCOPENIA IN RHEUMATOID ARTHRITIS
Authors: T. H. Li, C. C. Chuang, Y. S. Chang, C. C. Lai, C. F. Su, C. W. Liu, Y. Y. Yang, H. T. Liao, C. Y. Tsai
Journal: Annals of the Rheumatic Diseases (2020)

Background: Sarcopenia is an essential issue in elderly or chronically ill subjects, and a recent surge of research on sarcopenia in patients with rheumatoid arthritis (RA) has emerged; however, the results remains controversial. Objectives: To assess the prevalence and risk factors of sarcopenia in patients with RA. Methods: We searched the studies investigating the prevalence and risk factors of sarcopenia in PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), AiritiLibrary, Chinese Electronic Periodicals Service (CEPS) and China National Knowledge Infrastructure (CNKI) Database from inception to October 5, 2019. Effects regarding prevalence and the associated risk factors were extracted and evaluated by random-effect model. Sensitivity analysis was performed for the effects. Results: After searching, twenty studies containing 3,663 RA subjects were identified, and the pooled prevalence was 35%, among which the prevalence in male and female were 39.8% and 33.3% respectively. Twelve studies reported various risk factors, and therein which had been mentioned in more than two studies were included for meta-analysis, yielding age (odds ratio [OR] 1.168, 95% confidence interval [CI] 1.032-1.322, P =0.014), female (OR 4.438, 95% CI 1.857-10.605, P &lt; 0.001), CRP (OR 1.797, 95% CI 1.422-2.272, P &lt; 0.001), HAQ (OR 1.756, 95% CI 1.235-2.496, P=0.002) and RF seropositivity (OR 1.935, 95% CI 1.335-2.804, P &lt; 0.001) were significantly associated with sarcopenia in subjects with RA. There was no alteration of the results after removal any of studies in sensitivity analysis. Conclusion: Our meta-analysis demonstrated the prevalence and associated risk factors of sarcopenia in RA. More research was still warranted to clarify the relationship. References: [1]Ngeuleu A, Allali F, Medrare L, Madhi A, Rkain H, Hajjaj-Hassouni N. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017;37:1015-20. [2]Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29:589-95. Disclosure of Interests: None declared
Overlay Between Th1 and Th2 pathways in Patients with Common Variable Immunodeficiency and Allergic disease
Authors: Seemal Awan, Pavan Nataraj, Martin Maldonado-Puebla, Pooja Dave, Veronica Mark, Zachary Falk, Annette Aldous, Daniel Ein
Journal: Journal of Allergy and Clinical Immunology (2021)
Measurement and prediction of the severity of postinflammatory dyspigmentation after resolution of psoriatic plaques in patients treated with biologic therapy
Authors: Hsien-Yi Chiu, Nien-Feng Chang Liao, Rosaline Chung-yee Hui, Yu-Jr Lin, Ya-Chu Tsai, Yu-Huei Huang
Journal: Journal of the American Academy of Dermatology (2021)
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy
Authors: Ling Yu, Zhenjie Wang, Zhuomao Mo, Binhua Zou, Yuanyuan Yang, Rui Sun, Wen Ma, Meng Yu, Shijun Zhang, Zhiqiang Yu
Journal: Acta Pharmaceutica Sinica B (2021)

Hepatocellular carcinoma (HCC) has been known as the second common leading cancer worldwide, as it responds poorly to both chemotherapy and medication. Triptolide (TP), a diterpenoid triepoxide, is a promising treatment agent for its effective anticancer effect on multiple cancers including HCC. However, its clinical application has been limited owing to its severe systemic toxicities, low solubility, and fast elimination in the body. Therefore, to overcome the above obstacles, photo-activatable liposomes (LP) integrated with both photosensitizer Ce6 and chemotherapeutic drug TP (TP/Ce6-LP) was designed in the pursuit of controlled drug release and synergetic photodynamic therapy in HCC therapy. The TP encapsulated in liposomes accumulated to the tumor site due to the enhanced permeability and retention (EPR) effect. Under laser irradiation, the photosensitizer Ce6 generated reactive oxygen species (ROS) and further oxidized the unsaturated phospholipids. In this way, the liposomes were destroyed to release TP. TP/Ce6-LP with NIR laser irradiation (TP/Ce6-LP+L) showed the best anti-tumor effect both in vitro and in vivo on a patient derived tumor xenograft of HCC (PDXHCC). TP/Ce6-LP significantly reduced the side effects of TP. Furthermore, TP/Ce6-LP+L induced apoptosis through a caspase-3/PARP signaling pathway. Overall, TP/Ce6-LP+L is a novel potential treatment option in halting HCC progression with attenuated toxicity.
Lower Airway Dysbiosis Exacerbates Lung Cancer
Authors: Laurence Zitvogel, Guido Kroemer
Journal: Cancer Discovery (2021)

Accumulating evidence supports the impact of the gut microbiota on the clinical efficacy of cancer immunotherapies against extraintestinal tumors, but it has not yet been addressed whether local commensals could also dictate the prognosis of patients with cancer. In this issue of Cancer Discovery, Tsay and colleagues demonstrate that the lower airway microbiota may harbor oral commensals that turn on IL17-mediated inflammatory pathways and reprogram host transcription to exacerbate lung cancer progression.See related article by Tsay et al., p. 293.
Vitamin B12 Associated to Total Body Fat in Healthy Non-Obese Adults According to Insulin Resistance Status
Authors: Christoper A. Alarcon-Ruiz, Betzi Pantoja-Torres, Mirella Guarnizo-Poma, Herbert Lazaro-Alcantara, Socorro Paico-Palacios, Miguel G. Moscoso-Porras, Vicente Benites-Zapata, Insulin Resistance
Journal: Metabolism (2021)